Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Bernick

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Menopause (New York, N.Y.)|October 31, 2019
Physical characteristics and properties of estradiol softgel vaginal insertsJames A Simon, James H Pickar, Annette M Shadiack, et al.
Menopause (New York, N.Y.)|April 19, 2017
Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trialJames A Simon, David F Archer, Risa Kagan, et al.
Menopause (New York, N.Y.)|November 6, 2019
Early onset of action with a 17β-estradiol, softgel, vaginal insert for treating vulvar and vaginal atrophy and moderate to severe dyspareuniaGinger Constantine, Leah S Millheiser, Andrew M Kaunitz, et al.
Journal of Women'S Health (2002)|March 30, 2017
Consistency of Effect with a Low-Dose, Estradiol Vaginal Capsule (TX-004HR): Evaluating Improvement in Vaginal Physiology and Moderate-to-Severe Dyspareunia in Subgroups of Postmenopausal WomenGinger D Constantine, Celine Bouchard, James H Pickar, et al.
Menopause (New York, N.Y.)|December 6, 2018
Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptomsGinger D Constantine, Dennis A Revicki, Risa Kagan, et al.
Current Medical Research and Opinion|September 22, 2018
Estradiol vaginal inserts (4 µg and 10 µg) for treating moderate to severe vulvar and vaginal atrophy: a review of phase 3 safety, efficacy and pharmacokinetic dataGinger D Constantine, James A Simon, James H Pickar, et al.
Menopause (New York, N.Y.)|February 15, 2017
Patient acceptability and satisfaction with a low-dose solubilized vaginal estradiol softgel capsule, TX-004HRSheryl A Kingsberg, Robin Kroll, Irwin Goldstein, et al.
The Journal of Sexual Medicine|October 4, 2016
TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women With Vulvar and Vaginal Atrophy: The REJOICE TrialSheryl A Kingsberg, Leonard Derogatis, James A Simon, et al.
Menopause (New York, N.Y.)|December 22, 2016
TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiolDavid F Archer, Ginger D Constantine, James A Simon, et al.
Contraception|March 31, 2021
Segesterone acetate serum levels with a regression model of continuous use of the segesterone acetate/ethinyl estradiol contraceptive vaginal systemJames H Liu, Marlena Plagianos, David F Archer, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Menopause (New York, N.Y.)|October 31, 2019
Physical characteristics and properties of estradiol softgel vaginal insertsJames A Simon, James H Pickar, Annette M Shadiack, et al.
Menopause (New York, N.Y.)|April 19, 2017
Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trialJames A Simon, David F Archer, Risa Kagan, et al.
Menopause (New York, N.Y.)|November 6, 2019
Early onset of action with a 17β-estradiol, softgel, vaginal insert for treating vulvar and vaginal atrophy and moderate to severe dyspareuniaGinger Constantine, Leah S Millheiser, Andrew M Kaunitz, et al.
Journal of Women'S Health (2002)|March 30, 2017
Consistency of Effect with a Low-Dose, Estradiol Vaginal Capsule (TX-004HR): Evaluating Improvement in Vaginal Physiology and Moderate-to-Severe Dyspareunia in Subgroups of Postmenopausal WomenGinger D Constantine, Celine Bouchard, James H Pickar, et al.
Menopause (New York, N.Y.)|December 6, 2018
Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptomsGinger D Constantine, Dennis A Revicki, Risa Kagan, et al.
Current Medical Research and Opinion|September 22, 2018
Estradiol vaginal inserts (4 µg and 10 µg) for treating moderate to severe vulvar and vaginal atrophy: a review of phase 3 safety, efficacy and pharmacokinetic dataGinger D Constantine, James A Simon, James H Pickar, et al.
Menopause (New York, N.Y.)|February 15, 2017
Patient acceptability and satisfaction with a low-dose solubilized vaginal estradiol softgel capsule, TX-004HRSheryl A Kingsberg, Robin Kroll, Irwin Goldstein, et al.
The Journal of Sexual Medicine|October 4, 2016
TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women With Vulvar and Vaginal Atrophy: The REJOICE TrialSheryl A Kingsberg, Leonard Derogatis, James A Simon, et al.
Menopause (New York, N.Y.)|December 22, 2016
TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiolDavid F Archer, Ginger D Constantine, James A Simon, et al.
Contraception|March 31, 2021
Segesterone acetate serum levels with a regression model of continuous use of the segesterone acetate/ethinyl estradiol contraceptive vaginal systemJames H Liu, Marlena Plagianos, David F Archer, et al.
Pageof 4